References
  1. Tans G, Bouma BN, Büller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med 2003; 3 (1): 61-68.
  2. O’Brien SH. Contraception-Related Venous Thromboembolism in Adolescents. Semin Thromb Hemost 2014; 40: 66-71.
  3. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow up study, Denmark 2001-10. BMJ 2012; 344: e2990.
  4. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001-9 BMJ 2011; 343: d6423.
  5. Jick SS, Kaye JA, Russman S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006; 73 (6): 566-70.
  6. Ogden CL, Carroll ED, Fryar CD et al. Prevalence of obesity among adults and youth United States 2011-2014: NCHS Data Brief 2015; (219): 1-8.
  7. Ward Z, Bleich SN, Cradock AL, Barrett JL et al. Projected U.S State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381: 2440-2450.
  8. Pannaciulli N, DeMitrio V, Marino R et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10: 17-25.
  9. Juhar-Vague I, Alessi MC, Mauri A et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579.
  10. Mertens I, Van Gall LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
  11. Sydney S, Petitti DB, Soff GA et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004; 70: 3-10.
  12. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events; A systematic review. Contraception 2016; 94: 590-604.
  13. Abdollahi M, Cushman M, Roseendal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493.
  14. Pomp ER, LeCessie S, Rosendaal FR et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use as prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
  15. Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: a five year national case-control study. Contraception 2002; 65 (3): 197-205.
  16. Pillai P, Bonny AE, O’Brien SH. Contraception-related venous thromboembolism in a Pediatric Institution. J Pediatr Adolesc Gynecol 2013; 26: 186-188.
  17. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update . 1999;5(6):672-680.
  18. Jeanet M. Kemmeren, Ale Algra, Joost C. M. Meijers, Guido Tans, Bonno N. Bouma, Joyce Curvers, Jan Rosing, Diederick E. Grobbee; Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood  2004; 103 (3): 927–933.
  19. Merki-Feld GS, Skouby S, Serfaty D et al. European Society of contraception Statement on contraception in obese women. Eu J Contracept Reprod Health Care 2015; 20: 19-28.
  20. Van Vlijmen EF, Veeger NJ, Middeldorp S et al. Thrombotic risk during oral contraceptive use and pregnancy in women with Factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118 (8): 2055-2061.
  21. Lidegaard O. Hormonal contraception, thrombosis and age. Expert Opin Drug Saf 2014; 13 (10): 1353-1360.
  22. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ . 2011;183(18):E1319-E1325.
  23. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287-294.
  24. World Health Organization Medical Eligibility Criteria for Contraceptive Use. Geneva, Switzerland: World Health Organization: 2009.
  25. Faculty of Sexual & Reproductive Health-Care. UK medical eligibility for contraceptive use. Available at www. Ffprhc.org.uk/admin/uploads/UKMEC 2009.pdf. Accessed December 23, 2019.
  26. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion: Centers for Disease Control and Prevention; Farr S, Folger SG, Paulen M, et al. US medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed. MMWR Recomm Rep 2010; 59 (RR-4). 1-86.